Replies to post #2582 on Biotech Values

[Biowatch]

GENR UPDATED INSIDER SHAREHOLDINGS

Executive officers

ROY C. LEVITT, CEO
259K shares
1.185M options at exercise prices of $0.40-$11.63

JOHN A. SKOLAS, CFO
57.2K shares (joined 10/2003)
300K options at $0.00-$5.19

JOHN L. ARMSTRONG, Jr., EVP (Operations)
50K shares (joined 10/2003)
350K options at $3.19-$4.45

MICHAEL J. GHAST. CMO
50K shares at $0.00 (joined 2/2005)
100K options at $3.00

LAURA GRABULTZ (Executive Director Regulatory Affairs)
(joined 7/2004)

JOHN J. McCLOSKEY, VP (Manufacturing)
(joined 7/2004)

Independent directors

OSAGIE O. IMASOGIE
83K shares (bought on open market between $3.06-3.96 in 5/2004 & 8/2004)
40K options at $3.50-$3.96

R. FRANK R. ECOCK
60K shares
90K options at $0.40-$4.65

ROBERT F. SHAPIRO
188K shares
120K options at $0.40-$10.19

ZOLA P. HOROVITZ
30K shares
150K options at $0.40-$10.13

JAMES B. WYNGAARDEN
5k shares
120K options at $0.40-$10.19

Miscellaneous

ROGER VOGEL, Consultant
(Dr. Vogel, who joined GENR during 3/2004 as the acting Chief medical Officer, is not formally an officer of the company and hence does not file insider trades with the SEC. Remains as a consultant after the appointment of Ghast as CMO.)

Kenneth Holroyd, the former COO, left the company on 3/26/04. On that date, he held 39K shares and 661K options exercisable at $0.40-8.00. It is not known how many shares and options are still held by Dr. Holroyd.

Angeline Shashlo, the former SVP, Regulatory Affairs, joined GENR in 6/2002, and left the company by 7/26/2004. At that time she held 50K restricted shares (none of which had vested and therefore could not be exercised) and 175K options at $0.40-$2.74. It is not known how many shares and options are still held by Shashlo. Laura Grabultz has taken over her duties.